<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33865343</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2377</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>17</Day></PubDate></JournalIssue><Title>BMC neurology</Title><ISOAbbreviation>BMC Neurol</ISOAbbreviation></Journal><ArticleTitle>Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study.</ArticleTitle><Pagination><StartPage>164</StartPage><MedlinePgn>164</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">164</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12883-021-02187-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease with great heterogeneity. Biological prognostic markers are needed for the patients to plan future supportive treatment, palliative treatment, and end-of-life decisions. In addition, prognostic markers are greatly needed for the randomization in clinical trials.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to test the ALS Functional Rating Scale-Revised (ALSFRS-R) progression rate (&#x394;FS) as a prognostic marker of survival in a Danish ALS cohort.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The ALSFRS-R score at test date in association with duration of symptoms, from the onset of symptoms until test date, (defined as &#x394;FS') was calculated for 90 Danish patients diagnosed with either probable or definite sporadic ALS. Median survival time was then estimated from the onset of symptoms until primary endpoint (either death or tracheostomy). &#x394;FS' was subjected to survival analysis using Cox proportional hazards modelling, log-rank test, and Kaplan-Meier survival analysis.</AbstractText><AbstractText Label="RESULTS AND CONCLUSIONS" NlmCategory="CONCLUSIONS">Both &#x394;FS' and age was found to be strong predictors of survival of the Danish ALS cohort. Both variables are easily obtained at the time of diagnosis and could be used by clinicians and ALS patients to plan future supportive and palliative treatment. Furthermore, &#x394;FS', is a simple, prognostic marker that predicts survival in the early phase of disease as well as at later stages of the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kj&#xe6;ldgaard</LastName><ForeName>Anne-Lene</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Medicine, Department of Clinical Immunology Section 7631, Diagnostic Centre, Rigshospitalet, Ole Maaloesvej 26, DK-2200, Copenhagen N, Denmark. anne-lene.kjaeldgaard@regionh.dk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroanaesthesiology, Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark. anne-lene.kjaeldgaard@regionh.dk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pilely</LastName><ForeName>Katrine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Medicine, Department of Clinical Immunology Section 7631, Diagnostic Centre, Rigshospitalet, Ole Maaloesvej 26, DK-2200, Copenhagen N, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsen</LastName><ForeName>Karsten Skovgaard</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Neuroanaesthesiology, Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jessen</LastName><ForeName>Anders Hedegaard</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Institute of Actuarial Science, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lauritsen</LastName><ForeName>Anne &#xd8;berg</ForeName><Initials>A&#xd8;</Initials><AffiliationInfo><Affiliation>Department of Neuroanaesthesiology, Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Stephen W&#xf8;rlich</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svenstrup</LastName><ForeName>Kirsten</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karlsborg</LastName><ForeName>Merete</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thagesen</LastName><ForeName>Helle</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Roskilde University Hospital, Zealand University Hospital, Roskilde, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blaabjerg</LastName><ForeName>Morten</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Roskilde University Hospital, Zealand University Hospital, Roskilde, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>The&#xf3;d&#xf3;rsd&#xf3;ttir</LastName><ForeName>&#xc1;sta</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>Department of Neurology, Odense University Hospital, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elmo</LastName><ForeName>Elisabeth Gundtoft</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf8;ller</LastName><ForeName>Anette Torvin</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonefeld</LastName><ForeName>Lone</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Odense University Hospital, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>Mia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Roskilde University Hospital, Zealand University Hospital, Roskilde, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garred</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Medicine, Department of Clinical Immunology Section 7631, Diagnostic Centre, Rigshospitalet, Ole Maaloesvej 26, DK-2200, Copenhagen N, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf8;ller</LastName><ForeName>Kirsten</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroanaesthesiology, Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Neurol</MedlineTA><NlmUniqueID>100968555</NlmUniqueID><ISSNLinking>1471-2377</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALSFRS-R slope</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Median survival time</Keyword><Keyword MajorTopicYN="N">Prognostic biomarker</Keyword></KeywordList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>18</Day><Hour>20</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33865343</ArticleId><ArticleId IdType="pmc">PMC8052712</ArticleId><ArticleId IdType="doi">10.1186/s12883-021-02187-8</ArticleId><ArticleId IdType="pii">10.1186/s12883-021-02187-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007;6(11):994&#x2013;1003. doi: 10.1016/S1474-4422(07)70265-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(07)70265-X</ArticleId><ArticleId IdType="pubmed">17945153</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118&#x2013;130. doi: 10.1159/000351153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10(5&#x2013;6):310&#x2013;323. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, Van Damme P. Diagnostic and prognostic performance of Neurofilaments in ALS. Front Neurol. 2018;9:1167. doi: 10.3389/fneur.2018.01167.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01167</ArticleId><ArticleId IdType="pmc">PMC6345692</ArticleId><ArticleId IdType="pubmed">30713520</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III) J Neurol Sci. 1999;169(1&#x2013;2):13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Cheng B, Salachas F, Pradat PF, Bruneteau G, Corcia P, Lacomblez L, Meininger V. Progression in ALS is not linear but is curvilinear. J Neurol. 2010;257(10):1713&#x2013;1717. doi: 10.1007/s00415-010-5609-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-010-5609-1</ArticleId><ArticleId IdType="pubmed">20532545</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, et al. The ALSFRSr predicts survival time in an ALS clinic population. Neurology. 2005;64(1):38&#x2013;43. doi: 10.1212/01.WNL.0000148648.38313.64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000148648.38313.64</ArticleId><ArticleId IdType="pubmed">15642901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, Shinoda K, Sugino M, Hanafusa T. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265&#x2013;267. doi: 10.1212/01.wnl.0000194316.91908.8a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000194316.91908.8a</ArticleId><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamin M, Bede P, Montuschi A, Pender N, Chio A, Hardiman O. Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. J Neurol. 2015;262(6):1447&#x2013;1454. doi: 10.1007/s00415-015-7731-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-015-7731-6</ArticleId><ArticleId IdType="pmc">PMC4469087</ArticleId><ArticleId IdType="pubmed">25860344</ArticleId></ArticleIdList></Reference><Reference><Citation>Nodera H, Izumi Y, Kaji R. New diagnostic criteria of ALS (Awaji criteria) Brain Nerve. 2007;59(10):1023&#x2013;1029.</Citation><ArticleIdList><ArticleId IdType="pubmed">17969342</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2000;1(5):293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Labra J, Menon P, Byth K, Morrison S, Vucic S. Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry. 2016;87(6):628&#x2013;632. doi: 10.1136/jnnp-2015-310998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310998</ArticleId><ArticleId IdType="pubmed">26152368</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Cheung YK. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;67(7):1314&#x2013;1315. doi: 10.1212/01.wnl.0000243812.25517.87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000243812.25517.87</ArticleId><ArticleId IdType="pubmed">17030785</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, de Jongh AD, Nikolakopoulos S, McDermott CJ, Eijkemans MJC, Roes KCB, et al. An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2021:1&#x2013;8. 10.1080/21678421.2021.1879865.</Citation><ArticleIdList><ArticleId IdType="pubmed">33527843</ArticleId></ArticleIdList></Reference><Reference><Citation>Verschueren A. Motor neuropathies and lower motor neuron syndromes. Rev Neurol. 2017;173(5):320&#x2013;325. doi: 10.1016/j.neurol.2017.03.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2017.03.018</ArticleId><ArticleId IdType="pubmed">28434507</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, Martin S, McDermott CJ, Thompson AG, Pinto S, Kobeleva X, Rosenbohm A, Stubendorff B, Sommer H, Middelkoop BM, Dekker AM, van Vugt JJFA, van Rheenen W, Vajda A, Heverin M, Kazoka M, Hollinger H, Gromicho M, K&#xf6;rner S, Ringer TM, R&#xf6;diger A, Gunkel A, Shaw CE, Bredenoord AL, van Es MA, Corcia P, Couratier P, Weber M, Grosskreutz J, Ludolph AC, Petri S, de Carvalho M, van Damme P, Talbot K, Turner MR, Shaw PJ, al-Chalabi A, Chi&#xf2; A, Hardiman O, Moons KGM, Veldink JH, van den Berg LH. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423&#x2013;433. doi: 10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Taylor AA, Beaulieu D, Meng L, Bian A, Andrews J, Keymer M, Ennist DL, Ravina B. Improved stratification of ALS clinical trials using predicted survival. Ann Clin Transl Neurol. 2018;5(4):474&#x2013;485. doi: 10.1002/acn3.550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.550</ArticleId><ArticleId IdType="pmc">PMC5899911</ArticleId><ArticleId IdType="pubmed">29687024</ArticleId></ArticleIdList></Reference><Reference><Citation>Grollemund V, Chat GL, Secchi-Buhour MS, Delbot F, Pradat-Peyre JF, Bede P, Pradat PF. Development and validation of a 1-year survival prognosis estimation model for amyotrophic lateral sclerosis using manifold learning algorithm UMAP. Sci Rep. 2020;10(1):13378. doi: 10.1038/s41598-020-70125-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-70125-8</ArticleId><ArticleId IdType="pmc">PMC7414917</ArticleId><ArticleId IdType="pubmed">32770027</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Al-Chalabi A, Baker MR, Cui LY, de Carvalho M, Eisen A, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131(8):1975&#x2013;1978. doi: 10.1016/j.clinph.2020.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2020.04.005</ArticleId><ArticleId IdType="pubmed">32387049</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakore NJ, Lapin BR, Pioro EP. Trajectories of impairment in amyotrophic lateral sclerosis: insights from the pooled resource open-access ALS clinical trials cohort. Muscle Nerve. 2018;57(6):937&#x2013;945. doi: 10.1002/mus.26042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26042</ArticleId><ArticleId IdType="pubmed">29244213</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster LA, Salajegheh MK. Motor neuron disease: pathophysiology, diagnosis, and management. Am J Med. 2019;132(1):32&#x2013;37. doi: 10.1016/j.amjmed.2018.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2018.07.012</ArticleId><ArticleId IdType="pubmed">30075105</ArticleId></ArticleIdList></Reference><Reference><Citation>Kj&#xe6;ldgaard AL, Pilely K, Olsen KS, Lauritsen A, Pedersen SW, M&#xf8;ller K, et al. Amyotrophic lateral sclerosis and the innate immune system: protocol for establishing a biobank and statistical analysis plan. BMJ Open. 2020;10(8):e037753. doi: 10.1136/bmjopen-2020-037753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-037753</ArticleId><ArticleId IdType="pmc">PMC7409992</ArticleId><ArticleId IdType="pubmed">32759248</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>